Systemic Lupus Erthematosus (SLE)NCT07719322
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
An observational study of Systemic Lupus Erthematosus (SLE) and Lupus Nephritis (LN), run by Assiut University at 1 site in Egypt.
Trial summary
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
- How many people
- 156 participants
- Where
- 1 siteEgypt
- Study dates
- Jul 2026to Jul 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged ≥18 years Diagnosed as SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus including patients with and without Lupus nephritis recruited from Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics)
Who may be able to join
- Adults aged ≥18 years
- Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus.
- Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis.
Who cannot join
- Established cardiovascular disease (MI, stroke, PAD)
- Diabetes mellitus
- Hypertension
- Patient with CKD
- infections
- other autoimmune diseases
Show all 12Show fewer
- Pregnancy
- Malignancy
- chronic liver disease
- Dyslipidemia
- Obesity
- Patients on lipid lowering therapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Assuit university hospitals
Asyut, Assuit
Nada Abdelsalam, MSc, +20 01003562354, nada011450@med.aun.edu.eg
About this study
Official title: Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.
In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis
Read the detailed description
the study is asingle center observational study will be conducted at Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics) including :Full history taking and thorough clinical examination including:
- Demographic Information: Collect data on age, gender, duration of illness, and relevant medical history.
- Body Mass Index (BMI)
- smoking status and Medications history as (corticosteroids, immunosuppressants and anti lipidemic drugs to be excluded)
- Clinical Assessment: patients diagnosed as SLE according to 2019 EULAR/ACR classification criteria. and lupus nephritis (LN) , classified according to the 2018 ISN/RPS classification of lupus nephritis.and Assessment of SLE disease activity according to SLEADI-2K score.
- Laboratory Tests:
- Combelete blood count (CBC)
- Lipid profile ( fasting TGS ,total cholesterol, LDL, HDL, VLDL)
- Fasting blood glucose (mg/Dl)
- Kidney function test (Serum Creatinine ,blood urea nitrogen)
- eGFR
- CRP
- Erthrocyte sedimentation rate (ESR)
- Autoantibody Profiles: ANA, anti-dsDNA
- Complement Levels: C3, C4
- Urinary protein excretion (24-hour urinary protein )
- Homocysteine
- Serum uric acid
- Renal biobsy
- Indices calculation:
- Triglyceride-Glucose (TyG) Index
- The CRP_TYG index _- Carotid Ultrasonography
- Keywords
- triglyceride-glucose index, subclinical atherosclerosis, cardiovascular risk
- Medical subject headings
- Lupus Nephritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SLE without nephritis | Not described | |
| SLE with nephritis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN).
Measured: baseline (at enrollment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study startJul 2026 (estimated)
- Primary completionJul 2028 (estimated)
- Study completionJul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Lupus Erthematosus (SLE)Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 156 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nada Abdelsalam Hasan, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07719322
- Sponsor's protocol ID
- TYG index and CVS risks in LN
- Status last verified
- Jul 2026
- First submitted
- 18 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University
- ClinicalTrials.gov ID
- NCT07719322
- Acronym / sponsor ID
- TYG index and CVS risks in LN
- Keywords
- triglyceride-glucose index, subclinical atherosclerosis, cardiovascular risk
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 156 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jul 2029 (estimated)
- First posted
- 22 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.
In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis
Detailed description
the study is asingle center observational study will be conducted at Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics) including :Full history taking and thorough clinical examination including:
- Demographic Information: Collect data on age, gender, duration of illness, and relevant medical history.
- Body Mass Index (BMI)
- smoking status and Medications history as (corticosteroids, immunosuppressants and anti lipidemic drugs to be excluded)
- Clinical Assessment: patients diagnosed as SLE according to 2019 EULAR/ACR classification criteria. and lupus nephritis (LN) , classified according to the 2018 ISN/RPS classification of lupus nephritis.and Assessment of SLE disease activity according to SLEADI-2K score.
- Laboratory Tests:
- Combelete blood count (CBC)
- Lipid profile ( fasting TGS ,total cholesterol, LDL, HDL, VLDL)
- Fasting blood glucose (mg/Dl)
- Kidney function test (Serum Creatinine ,blood urea nitrogen)
- eGFR
- CRP
- Erthrocyte sedimentation rate (ESR)
- Autoantibody Profiles: ANA, anti-dsDNA
- Complement Levels: C3, C4
- Urinary protein excretion (24-hour urinary protein )
- Homocysteine
- Serum uric acid
- Renal biobsy
- Indices calculation:
- Triglyceride-Glucose (TyG) Index
- The CRP_TYG index _- Carotid Ultrasonography
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SLE without nephritis | – | – |
| SLE with nephritis | – | – |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged ≥18 years Diagnosed as SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus including patients with and without Lupus nephritis recruited from Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics)
Key inclusion criteria (3 listed)
- Adults aged ≥18 years
- Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus.
Key exclusion criteria (12 listed)
- Established cardiovascular disease (MI, stroke, PAD)
- Diabetes mellitus
- Hypertension
- Patient with CKD
- infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN).
Time frame: baseline (at enrollment)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Systemic Lupus Erthematosus (SLE)
Recruiting
Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous
Systemic Lupus Erthematosus (SLE)
RecruitingPhase 1/2
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erthematosus
Not yet recruiting
Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus
Systemic Lupus Erthematosus, Fatigue
Not yet recruitingPhase 2/3
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
Systemic Lupus Erthematosus
Not yet recruiting
Team-based Implementation of Hypertension Management in Childhood Lupus
Systemic Lupus Erthematosus (SLE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Systemic Lupus Erthematosus (SLE) and Lupus Nephritis (LN), run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact nada abdelsalam nada abdelsalam hassan, MSc (+20 01003562354, nada011450@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN). (time frame: baseline (at enrollment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.